PCSK9 and cardiovascular disorder: Notably, despite the maximal reduction of LDL in this study, the presence of residual inflammatory risk (hsCRP ≥ 2 mg/L) still put the risk of future cardiovascular disease at a higher risk, whereas the use of PCSK9 inhibitors significantly reduced the risk of cardiovascular events in the high-risk population.